Long-acting opioids for chronic pain: pharmacotherapeutic opportunities to enhance compliance, quality of life, and analgesia.
about
Opioid analgesics and the risk of fractures in older adults with arthritisA randomized, double-blind comparison of OROS(R) hydromorphone and controlled-release morphine for the control of chronic cancer pain.An open-label, 1-year extension study of the long-term safety and efficacy of once-daily OROS(R) hydromorphone in patients with chronic cancer pain.Extended-release morphine sulfate in treatment of severe acute and chronic painPharmacoeconomics of opioid therapy for chronic non-malignant pain.Current aproach to cancer pain management: Availability and implications of different treatment options.Opioids for managing chronic non-malignant pain: safe and effective prescribing.The Potential Role of an Extended-Release, Abuse-Deterrent Oxycodone/Acetaminophen Fixed-Dose Combination Product for the Treatment of Acute PainSingle-dose pharmacokinetics of 2 or 3 tablets of biphasic immediate-release/extended-release hydrocodone bitartrate/acetaminophen (MNK-155) under fed and fasted conditions: two randomized open-label trials.Comparison of single-dose and multiple-dose pharmacokinetics between two formulations of hydrocodone bitartrate/acetaminophen: immediate-release versus biphasic immediate-release/extended releaseFive pitfalls in decisions about diagnosis and prescribingOnce-daily OROS hydromorphone for the management of chronic nonmalignant pain: a dose-conversion and titration studySingle- and multiple-dose pharmacokinetics of biphasic immediate-release/extended-release hydrocodone bitartrate/acetaminophen (MNK-155) compared with immediate-release hydrocodone bitartrate/ibuprofen and immediate-release tramadol HCl/acetaminopheAnatomy of the Pain Centre waiting list at the Centre hospitalier de l'Université de Montréal (CHUM)An explorative study to assess the association between health-related quality of life and the recommended phase II dose in a phase I trial: idarubicin-loaded beads for chemoembolisation of hepatocellular carcinoma.A comparison of long- and short-acting opioids for the treatment of chronic noncancer pain: tailoring therapy to meet patient needsPrescription of Long-Acting Opioids and Mortality in Patients With Chronic Noncancer PainMarkers of abuse liability of short- vs long-acting opioids in chronic pain patients: a randomized cross-over trial.The pharmacokinetics of a long-acting OROS hydromorphone formulation.Oral Human Abuse Potential of Oxycodone DETERx® (Xtampza® ER).Opioids: how to improve compliance and adherence.The appropriate treatment of chronic pain.Controlled release formulation of oxycodone in patients with moderate to severe chronic osteoarthritis: a critical review of the literature.Chronic pain among liver transplant candidates.Primary care considerations of the pharmacokinetics and clinical use of extended-release opioids in treating patients with chronic noncancer pain.Assessment of extended-release opioid analgesics for the treatment of chronic pain.Chronic pain treatment with opioid analgesics: benefits versus harms of long-term therapy.Long- or short-acting opioids for chronic non-malignant pain? A qualitative systematic review.A review of the literature on multiple factors involved in postoperative pain course and duration.Pharmacological Management of Cancer-Related Pain.Oxycodone extended release capsules for the treatment of chronic pain.Randomized, double-blind, placebo-controlled study of the efficacy and safety of biphasic immediate-release/extended-release hydrocodone bitartrate/acetaminophen tablets for acute postoperative pain.Prescription and administration of opioids to hospital in-patients, and barriers to effective use.Opioid utilization patterns among medicare patients with diabetic peripheral neuropathy.Safety and Tolerability of Biphasic Immediate-Release/Extended-Release Oxycodone/Acetaminophen Tablets: Analysis of 11 Clinical Trials.Comparing the Effect of Tampering on the Oral Pharmacokinetic Profiles of Two Extended-Release Oxycodone Formulations with Abuse-Deterrent Properties.Effect of long-term treatment of morphine on enzymes, oxidative stress indices and antioxidant status in male rat liver.Chronic pain and narcotics: a dilemma for primary care.OxyContin was submitted and justifiably approved by the agency as a 12-hour dosage form.Effect of Food on the Pharmacokinetics of Single- and Multiple-Dose Hydrocodone Extended Release in Healthy Subjects.
P2860
Q24607425-2A72475E-05AA-4ED4-8312-9D1EFD3D1E76Q33381853-B1CD199B-1575-4858-9CDB-C1777BF5D0F2Q33503399-01275088-E31D-40A9-B3F4-A99F8F68D014Q34418327-6C0E3A07-C0BA-48B8-8CA5-1EC001701A8CQ34544700-DDD4E5E2-E62A-4719-B3F8-304779ADB7BFQ34779398-92D628AF-629E-4773-8BB0-486838101E57Q35613260-D4AD10FD-690D-41F9-A294-B5540DADD0FDQ35804625-310DF2F0-BAA2-413E-9E2F-2A72615807D1Q35854721-F63E977B-D59E-4E97-8B30-C979B52832FBQ36068596-18C21D35-7C0D-4E7B-84AF-185ECB927093Q36085437-B90C9868-4D6E-49A2-BB67-E0629812D689Q36088599-8CAAEA1C-443B-4172-B66D-F43C4F68B58DQ36137313-5F2B8EF6-146B-4BCD-9F70-A299EB3D32AAQ37017868-C90B6C23-5CBE-4CC5-8E98-801D08AFDF41Q37063738-7A43DF5E-2D89-4C8D-AB97-7B3E060624BAQ37246245-81256F8A-59D0-4289-AAE8-EEB21FFEF9D3Q37272148-74894805-8C2B-47F0-A52C-E340F31F4167Q37376570-FA243E91-D5FB-469D-8C74-47C23D71EE01Q37644498-915C27E4-AAD0-4F2A-8FF7-1A464EAD81F0Q37717944-A1CC377A-2C90-49A5-A567-09BC6F66BB48Q37853618-E5A5088E-0ECF-4BED-9273-3EB540AD34C9Q37987194-446B1F46-6BBD-4502-BF0E-955E7B60375AQ38008646-3F3961B4-57FF-4DAF-8FC2-5967FB624464Q38063055-82C5CCD4-B997-4F52-A882-44003D03F377Q38079923-24535474-3A0F-4758-A131-DD2638CA7689Q38092855-CF2CCB29-2045-4F65-8D7E-320555061A21Q38157029-895108D6-3D0E-4E6F-8C57-A5F1D1755856Q38195081-C3F74A44-BCCB-4610-9F93-CD6892F5722FQ38241633-815AA709-A771-48F6-A1FE-3D4772966D79Q38672359-782964BA-119A-414D-B7B3-9CDA09E804B4Q38917891-EB722C02-53BC-4CEF-81CC-A83E758AAC7AQ39192192-904863CE-E83A-4AD1-B20C-98E438CEE8A2Q39295471-F2E7C7AF-10AD-4E82-A036-5BA9CA0D5FD6Q39890252-970AECF0-C97E-462F-9CA8-4D6A51E36221Q40619029-92006468-4C0B-4001-A7FA-C16725E9EED4Q40800503-2DB1D4AF-9EAA-4661-955B-8414D528A48AQ41382225-57136360-6BA6-4B65-881F-830C39B2E4B1Q42348119-9DD9CD8A-1081-492A-8077-447A59135F04Q42396049-F4395961-E604-42E9-A3FB-14F293E3C593Q42693173-05A9FC72-69C7-4BEE-9299-50998CBCF293
P2860
Long-acting opioids for chronic pain: pharmacotherapeutic opportunities to enhance compliance, quality of life, and analgesia.
description
2001 nî lūn-bûn
@nan
2001 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Long-acting opioids for chroni ...... uality of life, and analgesia.
@ast
Long-acting opioids for chroni ...... uality of life, and analgesia.
@en
Long-acting opioids for chroni ...... uality of life, and analgesia.
@nl
type
label
Long-acting opioids for chroni ...... uality of life, and analgesia.
@ast
Long-acting opioids for chroni ...... uality of life, and analgesia.
@en
Long-acting opioids for chroni ...... uality of life, and analgesia.
@nl
prefLabel
Long-acting opioids for chroni ...... uality of life, and analgesia.
@ast
Long-acting opioids for chroni ...... uality of life, and analgesia.
@en
Long-acting opioids for chroni ...... uality of life, and analgesia.
@nl
P921
P1476
Long-acting opioids for chroni ...... uality of life, and analgesia.
@en
P2093
McCarberg BH
P304
P356
10.1097/00045391-200105000-00006
P577
2001-05-01T00:00:00Z